Will There Be a Vaccine to Prevent HCV Infection?

 

 Permissions and Reprints

Abstract

Prevention of hepatitis C virus (HCV) infection by vaccination has been a priority since discovery of the virus and the need has not diminished over the past 25 years. Infection rates are increasing in developed countries because of intravenous drug use. Reducing transmission will be difficult without a vaccine to prevent persistence of primary infections, and also secondary infections that may occur after cure of chronic hepatitis C with increasingly effective direct-acting antiviral (DAA) regimens. Vaccine need is also acute in resource poor countries where most new infections occur and DAAs may be unaffordable. Spontaneous resolution of HCV infection confers durable protection, but mechanisms of immunity remain obscure and contested in the context of vaccine design. A vaccine must elicit a CD4+ helper T cell response that does not fail during acute infection. The need for neutralizing antibodies versus cytotoxic CD8+ T cells is unsettled and reflected in the design of two very different vaccines evaluated in humans for safety and immunogenicity. Here we review the status of vaccine development and the scientific and practical challenges that must be met if the burden of liver disease caused by HCV is to be reduced or eliminated.

• References

• 1 Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244 (4902): 359-362
  CrossrefPubMedGoogle Scholar
• 2 Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57 (4) 1333-1342
  CrossrefPubMedGoogle Scholar
• 3 Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19 (7) 837-849
  CrossrefPubMedGoogle Scholar
• 4 Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138 (2) 513-521 , e1–e6
  CrossrefPubMedGoogle Scholar
• 5 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19 (7) 850-858
  CrossrefPubMedGoogle Scholar
• 6 Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013; 21 (12) 625-633
  CrossrefPubMedGoogle Scholar
• 7 Torti C, Focà A, Carosi G. Towards HCV extinction with modern HCV treatment? “Yes we can!”. BMC Infect Dis 2012; 12 (Suppl. 02) S1
  CrossrefPubMedGoogle Scholar
• 8 Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis 2012; 55 (Suppl. 01) S3-S9
  CrossrefPubMedGoogle Scholar
• 9 Lin RH, Hwang YW, Yang BC, Lin CS. TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. J Immunol 1997; 158 (2) 598-603
  PubMedGoogle Scholar
• 10 Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60 (17) 537-541
  PubMedGoogle Scholar
• 11 McNamara BC, Losikoff PT, Huguenin L, Macalino GE, Rich JD, Gregory SH. Increasing Hepatitis C Prevalence and Associated Risk Behaviors among Incarcerated Young Adults. J Urban Health 2013;
  PubMedGoogle Scholar
• 12 Centers for Disease Control and Prevention (CDC). Notes from the field : hepatitis C virus infections among young adults—rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep 2012; 61 (19) 358
  PubMedGoogle Scholar
• 13 Rolls DA, Sacks-Davis R, Jenkinson R , et al. Hepatitis C transmission and treatment in contact networks of people who inject drugs. PLoS ONE 2013; 8 (11) e78286
  CrossrefPubMedGoogle Scholar
• 14 Martin NK, Vickerman P, Grebely J , et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58 (5) 1598-1609
  CrossrefPubMedGoogle Scholar
• 15 Hahn JA, Wylie D, Dill J , et al. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 2009; 1 (1) 47-57
  CrossrefPubMedGoogle Scholar
• 16 Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15 (1) 7-16
  CrossrefPubMedGoogle Scholar
• 17 Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010; 107 (33) 14757-14762
  CrossrefPubMedGoogle Scholar
• 18 Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol 2012; 55 (4) 296-302
  CrossrefPubMedGoogle Scholar
• 19 Smith DB, Bukh J, Kuiken C , et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: Updated criteria and assignment web resource. Hepatology 2014; 59 (1) 318-327
  CrossrefPubMedGoogle Scholar
• 20 Zubkova I, Choi YH, Chang E , et al. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 2009; 27 (19) 2594-2602
  CrossrefPubMedGoogle Scholar
• 21 Puig M, Mihalik K, Tilton JC , et al. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006; 44 (3) 736-745
  CrossrefPubMedGoogle Scholar
• 22 Prince AM. Immunity in hepatitis C virus infection. Vox Sang 1994; 67 (Suppl. 03) 227-228
  CrossrefPubMedGoogle Scholar
• 23 Farci P, Alter HJ, Govindarajan S , et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258 (5079) 135-140
  CrossrefPubMedGoogle Scholar
• 24 Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspé G. Immunity in hepatitis C infection. J Infect Dis 1992; 165 (3) 438-443
  CrossrefPubMedGoogle Scholar
• 25 Major ME, Mihalik K, Puig M , et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002; 76 (13) 6586-6595
  CrossrefPubMedGoogle Scholar
• 26 Bassett SE, Guerra B, Brasky K , et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001; 33 (6) 1479-1487
  CrossrefPubMedGoogle Scholar
• 27 Lanford RE, Guerra B, Chavez D , et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004; 78 (3) 1575-1581
  CrossrefPubMedGoogle Scholar
• 28 Grakoui A, Shoukry NH, Woollard DJ , et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302 (5645) 659-662
  CrossrefPubMedGoogle Scholar
• 29 Shoukry NH, Grakoui A, Houghton M , et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197 (12) 1645-1655
  CrossrefPubMedGoogle Scholar
• 30 Prince AM, Brotman B, Lee DH , et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 2005; 192 (10) 1701-1709
  CrossrefPubMedGoogle Scholar
• 31 Grebely J, Prins M, Hellard M , et al; International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12 (5) 408-414
  CrossrefPubMedGoogle Scholar
• 32 Osburn WO, Fisher BE, Dowd KA , et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138 (1) 315-324
  CrossrefPubMedGoogle Scholar
• 33 Mehta SH, Cox A, Hoover DR , et al. Protection against persistence of hepatitis C. Lancet 2002; 359 (9316) 1478-1483
  CrossrefPubMedGoogle Scholar
• 34 Hara K, Rivera MM, Koh C , et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?. J Infect Dis 2014; 209 (1) 38-45
  CrossrefPubMedGoogle Scholar
• 35 Lee WM, Polson JE, Carney DS, Sahin B, Gale Jr M. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005; 192 (6) 1088-1092
  CrossrefPubMedGoogle Scholar
• 36 Semmo N, Lucas M, Krashias G, Lauer G, Chapel H, Klenerman P. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. Blood 2006; 107 (11) 4570-4571
  CrossrefPubMedGoogle Scholar
• 37 Krawczynski K, Alter MJ, Tankersley DL , et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173 (4) 822-828
  CrossrefPubMedGoogle Scholar
• 38 Morin TJ, Broering TJ, Leav BA , et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 2012; 8 (8) e1002895
  CrossrefPubMedGoogle Scholar
• 39 Lavillette D, Morice Y, Germanidis G , et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79 (10) 6023-6034
  CrossrefPubMedGoogle Scholar
• 40 Pestka JM, Zeisel MB, Bläser E , et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007; 104 (14) 6025-6030
  CrossrefPubMedGoogle Scholar
• 41 Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009; 136 (7) 2377-2386
  CrossrefPubMedGoogle Scholar
• 42 von Hahn T, Yoon JC, Alter H , et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132 (2) 667-678
  CrossrefPubMedGoogle Scholar
• 43 Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012; 205 (5) 763-771
  CrossrefPubMedGoogle Scholar
• 44 Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119 (7) 1745-1754
  CrossrefPubMedGoogle Scholar
• 45 Walker CM. Adaptive immunity to the hepatitis C virus. Adv Virus Res 2010; 78: 43-86
  PubMedGoogle Scholar
• 46 Shin EC, Park SH, Nascimbeni M , et al. The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol 2013; 87 (8) 4772-4777
  CrossrefPubMedGoogle Scholar
• 47 Zubkova I, Duan H, Wells F , et al. Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T-cells in immune-primed chimpanzees. Hepatology 2013;
  PubMedGoogle Scholar
• 48 Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L , et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012; 209 (1) 61-75
  CrossrefPubMedGoogle Scholar
• 49 Gerlach JT, Diepolder HM, Jung MC , et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117 (4) 933-941
  CrossrefPubMedGoogle Scholar
• 50 Bukh J, Thimme R, Meunier JC , et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol 2008; 82 (16) 8183-8195
  CrossrefPubMedGoogle Scholar
• 51 Rutebemberwa A, Ray SC, Astemborski J , et al. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 2008; 181 (12) 8215-8225
  CrossrefPubMedGoogle Scholar
• 52 Bengsch B, Seigel B, Ruhl M , et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010; 6 (6) e1000947
  CrossrefPubMedGoogle Scholar
• 53 Kasprowicz V, Kang YH, Lucas M , et al. Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution. J Virol 2010; 84 (3) 1656-1663
  CrossrefPubMedGoogle Scholar
• 54 Akazawa D, Moriyama M, Yokokawa H , et al. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology 2013; 145 (2) 447-455 , e1–e4
  CrossrefPubMedGoogle Scholar
• 55 Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239 (1) 99-108
  CrossrefPubMedGoogle Scholar
• 56 Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 2004; 22 (8) 991-1000
  CrossrefPubMedGoogle Scholar
• 57 Meunier JC, Gottwein JM, Houghton M , et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011; 204 (8) 1186-1190
  CrossrefPubMedGoogle Scholar
• 58 Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139 (3) 965-974
  CrossrefPubMedGoogle Scholar
• 59 Frey SE, Houghton M, Coates S , et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28 (38) 6367-6373
  CrossrefPubMedGoogle Scholar
• 60 Ray R, Meyer K, Banerjee A , et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 2010; 202 (6) 862-866
  CrossrefPubMedGoogle Scholar
• 61 Law JL, Chen C, Wong J , et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS ONE 2013; 8 (3) e59776
  CrossrefPubMedGoogle Scholar
• 62 Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 1999; 17 (15-16) 1992-2002
  CrossrefPubMedGoogle Scholar
• 63 Garrone P, Fluckiger AC, Mangeot PE , et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3 (94) 94ra71
  PubMedGoogle Scholar
• 64 Kong L, Giang E, Nieusma T , et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013; 342 (6162) 1090-1094
  CrossrefPubMedGoogle Scholar
• 65 Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44 (6) 959-968
  CrossrefPubMedGoogle Scholar
• 66 Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol 2013; 31: 443-473
  CrossrefPubMedGoogle Scholar
• 67 Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128 (2) 195-203
  CrossrefPubMedGoogle Scholar
• 68 Elmowalid GA, Qiao M, Jeong SH , et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 2007; 104 (20) 8427-8432
  CrossrefPubMedGoogle Scholar
• 69 Capone S, Meola A, Ercole BB , et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006; 80 (4) 1688-1699
  CrossrefPubMedGoogle Scholar
• 70 Fattori E, Zampaglione I, Arcuri M , et al. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther 2006; 13 (14) 1088-1096
  CrossrefPubMedGoogle Scholar
• 71 Jeong SH, Qiao M, Nascimbeni M , et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004; 78 (13) 6995-7003
  CrossrefPubMedGoogle Scholar
• 72 Lang Kuhs KA, Ginsberg AA, Yan J , et al. Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses. Mol Ther 2012; 20 (3) 669-678
  CrossrefPubMedGoogle Scholar
• 73 Polakos NK, Drane D, Cox J , et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 2001; 166 (5) 3589-3598
  CrossrefPubMedGoogle Scholar
• 74 Rollier C, Verschoor EJ, Paranhos-Baccala G , et al. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J Infect Dis 2005; 192 (5) 920-929
  CrossrefPubMedGoogle Scholar
• 75 Rollier C, Depla E, Drexhage JA , et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol 2004; 78 (1) 187-196
  CrossrefPubMedGoogle Scholar
• 76 Folgori A, Capone S, Ruggeri L , et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12 (2) 190-197
  CrossrefPubMedGoogle Scholar
• 77 Youn JW, Hu YW, Tricoche N , et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol 2008; 82 (21) 10896-10905
  CrossrefPubMedGoogle Scholar
• 78 Rollier CS, Paranhos-Baccala G, Verschoor EJ , et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007; 45 (3) 602-613
  CrossrefPubMedGoogle Scholar
• 79 Park SH, Shin EC, Capone S , et al. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology 2012; 143 (4) 1048-1060 , e4
  CrossrefPubMedGoogle Scholar
• 80 Barnes E, Folgori A, Capone S , et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4 (115) ra1
  PubMedGoogle Scholar
• 81 Cox AL, Thomas DL. Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis 2013; 57 (Suppl. 02) S46-S50
  CrossrefPubMedGoogle Scholar
• 82 Maher L, White B, Hellard M , et al. Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine 2010; 28 (45) 7273-7278
  CrossrefPubMedGoogle Scholar
• 83 Cox AL, Page K, Bruneau J , et al. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology 2009; 136 (1) 26-31
  CrossrefPubMedGoogle Scholar
• 84 Altevogt BM, Pankevich DE, Shelton-Davenport MK, Kahn JP , eds; Committee on the Use of Chimpanzees in Biomedical and Behavioral Research; National Research Council. Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity. Washington DC: National Academy of Sciences; 2011
  CrossrefGoogle Scholar
• 85 Billerbeck E, de Jong Y, Dorner M, de la Fuente C, Ploss A. Animal models for hepatitis C. Curr Top Microbiol Immunol 2013; 369: 49-86
  PubMedGoogle Scholar